A small proportion of patients (0.9%) switched to ADM tirzepatide
At Vive Ageless Weight Loss Centre, Rafael Olartecoechea provides semaglutide GLP-1 injections to assist individuals in losing weight, which can lessen the chance of many other major health disorders, such as cardiac issues
Outcomes Primary and Secondary Outcome Patients in the semaglutide study arm experienced a significantly lower rate of the primary outcome (cardiovascular composite end-point) (6.5% vs 8.0%, HR 0.80 (95% CI 0.72-0.90) No significant difference in rates of cardiac death (HR 0.85, 95% CI 0.71-1.01) however significantly lower rates of heart failure (HR 0.82, 95% CI 0.71-0.96) and all-cause mortality (HR 0.81, 95% CI 0.71-0.93) Adverse Events Rates and types of adverse events were fairly similar between control and intervention groups Permanent premature discontinuation of semaglutide or placebo occurred in 2351 patients (26.7%) in the semaglutide group and 2078 (23.6%) in the placebo group In obese and overweight patients with cardiovascular comorbidities but without diabetes, treatment with weekly semaglutide was superior to placebo in reducing the incidence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke at a mean follow-up of 39.8 months
Across both programs, researchers tracked adverse events meticulously, documenting everything from nausea to injection site reactions
Understanding Acid Reflux 2
Compare GLP-1 alternatives If you arrived here researching weight-loss options, the FDA-approved GLP-1 protocols are a sensible next reference point
